Literature DB >> 19864489

Fibroblast phenotype in male carriers of FMR1 premutation alleles.

Dolores Garcia-Arocena1, Jane E Yang, Judith R Brouwer, Flora Tassone, Christine Iwahashi, Elizabeth M Berry-Kravis, Christopher G Goetz, Allison M Sumis, Lili Zhou, Danh V Nguyen, Luis Campos, Erin Howell, Anna Ludwig, Claudia Greco, Rob Willemsen, Randi J Hagerman, Paul J Hagerman.   

Abstract

Fragile X-associated tremor/ataxia syndrome (FXTAS) is an adult-onset neurodegenerative disorder among carriers of premutation expansions (55-200 CGG repeats) of the fragile X mental retardation 1 (FMR1) gene. The clinical features of FXTAS, as well as various forms of clinical involvement in carriers without FXTAS, are thought to arise through a direct toxic gain of function of high levels of FMR1 mRNA containing the expanded CGG repeat. Here we report a cellular endophenotype involving increased stress response (HSP27, HSP70 and CRYAB) and altered lamin A/C expression/organization in cultured skin fibroblasts from 11 male carriers of premutation alleles of the FMR1 gene, including six patients with FXTAS and five premutation carriers with no clinical evidence of FXTAS, compared with six controls. A similar abnormal cellular phenotype was found in CNS tissue from 10 patients with FXTAS. Finally, there is an analogous abnormal cellular distribution of lamin A/C isoforms in knock-in mice bearing the expanded CGG repeat in the murine Fmr1 gene. These alterations are evident even in mouse embryonic fibroblasts, raising the possibility that, in humans, the expanded-repeat mRNA triggers pathogenic mechanisms early in development, thus providing a molecular basis for the neurodevelopmental abnormalities observed in some children and clinical symptoms in some adults who are carriers of premutation FMR1 alleles. Cellular dysregulation in fibroblasts represents a novel and highly advantageous model for investigating disease pathogenesis in premutation carriers and for quantifying and monitoring disease progression. Fibroblast studies may also prove useful in screening and testing the efficacy of therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19864489      PMCID: PMC2796892          DOI: 10.1093/hmg/ddp497

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  80 in total

Review 1.  Genes, plasticity and mental retardation.

Authors:  Cyrille Vaillend; Roseline Poirier; Serge Laroche
Journal:  Behav Brain Res       Date:  2008-01-31       Impact factor: 3.332

2.  ABBA regulates plasma-membrane and actin dynamics to promote radial glia extension.

Authors:  Juha Saarikangas; Janne Hakanen; Pieta K Mattila; Martin Grumet; Marjo Salminen; Pekka Lappalainen
Journal:  J Cell Sci       Date:  2008-04-14       Impact factor: 5.285

3.  Expanded clinical phenotype of women with the FMR1 premutation.

Authors:  Sarah M Coffey; Kylee Cook; Nicole Tartaglia; Flora Tassone; Danh V Nguyen; Ruiqin Pan; Hannah E Bronsky; Jennifer Yuhas; Mariya Borodyanskaya; Jim Grigsby; Melanie Doerflinger; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2008-04-15       Impact factor: 2.802

4.  Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey.

Authors:  Donald B Bailey; Melissa Raspa; Murrey Olmsted; David B Holiday
Journal:  Am J Med Genet A       Date:  2008-08-15       Impact factor: 2.802

5.  Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome.

Authors:  Jim Grigsby; Angela G Brega; Karen Engle; Maureen A Leehey; Randi J Hagerman; Flora Tassone; David Hessl; Paul J Hagerman; Jennifer B Cogswell; Rachael E Bennett; Kylee Cook; Deborah A Hall; Lanee S Bounds; Marsha J Paulich; Ann Reynolds
Journal:  Neuropsychology       Date:  2008-01       Impact factor: 3.295

6.  Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome.

Authors:  J R Brouwer; E Severijnen; F H de Jong; D Hessl; R J Hagerman; B A Oostra; R Willemsen
Journal:  Psychoneuroendocrinology       Date:  2008-05-12       Impact factor: 4.905

7.  Age-dependent cognitive changes in carriers of the fragile X syndrome.

Authors:  Kim M Cornish; Lexin Li; Cary S Kogan; Sebastien Jacquemont; Jeremy Turk; Ann Dalton; Randi J Hagerman; Paul J Hagerman
Journal:  Cortex       Date:  2007-12-23       Impact factor: 4.027

8.  Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS).

Authors:  J S Adams; P E Adams; D Nguyen; J A Brunberg; F Tassone; W Zhang; K Koldewyn; S M Rivera; J Grigsby; L Zhang; C DeCarli; P J Hagerman; R J Hagerman
Journal:  Neurology       Date:  2007-08-28       Impact factor: 9.910

Review 9.  Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines.

Authors:  Elizabeth Berry-Kravis; Liane Abrams; Sarah M Coffey; Deborah A Hall; Claudia Greco; Louise W Gane; Jim Grigsby; James A Bourgeois; Brenda Finucane; Sebastien Jacquemont; James A Brunberg; Lin Zhang; Janet Lin; Flora Tassone; Paul J Hagerman; Randi J Hagerman; Maureen A Leehey
Journal:  Mov Disord       Date:  2007-10-31       Impact factor: 10.338

10.  Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy.

Authors:  T Sullivan; D Escalante-Alcalde; H Bhatt; M Anver; N Bhat; K Nagashima; C L Stewart; B Burke
Journal:  J Cell Biol       Date:  1999-11-29       Impact factor: 10.539

View more
  34 in total

Review 1.  Neurodegeneration the RNA way.

Authors:  Abigail J Renoux; Peter K Todd
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 2.  Developments in RNA splicing and disease.

Authors:  Michael G Poulos; Ranjan Batra; Konstantinos Charizanis; Maurice S Swanson
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-01-01       Impact factor: 10.005

Review 3.  Fragile X: leading the way for targeted treatments in autism.

Authors:  Lulu W Wang; Elizabeth Berry-Kravis; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 4.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

5.  TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME.

Authors:  C Kağan Gürkan; Randi J Hagerman
Journal:  Res Autism Spectr Disord       Date:  2012-10-01

Review 6.  Advances in understanding the molecular basis of FXTAS.

Authors:  Dolores Garcia-Arocena; Paul J Hagerman
Journal:  Hum Mol Genet       Date:  2010-04-29       Impact factor: 6.150

7.  Reduced excitatory amino acid transporter 1 and metabotropic glutamate receptor 5 expression in the cerebellum of fragile X mental retardation gene 1 premutation carriers with fragile X-associated tremor/ataxia syndrome.

Authors:  Dalyir I Pretto; Madhur Kumar; Zhengyu Cao; Christopher L Cunningham; Blythe Durbin-Johnson; Lihong Qi; Robert Berman; Stephen C Noctor; Randi J Hagerman; Isaac N Pessah; Flora Tassone
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

8.  CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size.

Authors:  Anna Lisa Ludwig; Glenda M Espinal; Dalyir I Pretto; Amanda L Jamal; Gloria Arque; Flora Tassone; Robert F Berman; Paul J Hagerman
Journal:  Hum Mol Genet       Date:  2014-01-23       Impact factor: 6.150

9.  Screening for the presence of FMR1 premutation alleles in a Spanish population with fibromyalgia.

Authors:  Loreto Martorell; Mireia Tondo; Ferrán Garcia-Fructuoso; Montserrat Naudo; Cayetano Alegre; Josep Gamez; Jordi Genovés; Pilar Poo
Journal:  Clin Rheumatol       Date:  2012-08-18       Impact factor: 2.980

10.  Fragile X and autism: Intertwined at the molecular level leading to targeted treatments.

Authors:  Randi Hagerman; Gry Hoem; Paul Hagerman
Journal:  Mol Autism       Date:  2010-09-21       Impact factor: 7.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.